Health Condition 1: F33- Major depressive disorder, recurrent Health Condition 2: F413- Other mixed anxiety disorders
Conditions
Interventions
Sponsors
Torrent Pharmaceuticals Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female patients suffering from Co-morbid depression with anxiety treated with Escitalopram & Clonazepam FDC 2. Patients with HAM-A score more than or equal to 17 3. Patients with MADRS score more than or equal to 7 4. Patients followed-up for 12 weeks 5. Patients having at least 2 reported follow-up visits in 12 weeks following dose/therapy initiation [Baseline, Visit-1 & Visit-2 (Follow-up)].
Exclusion criteria
Exclusion criteria: 1. Cases with incomplete medical records 2. Any patients suffering from Treatment Resistant Depression (TRD)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Occurrence of AE/SAE/Discontinuation from ESC-CZP FDC therapy - Change from baseline in HAM-A & MADRS scores from baseline to 4th week & 12th week. Timepoint: Baseline, 4 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| - Usage pattern for Escitalopram & Clonazepam FDC such as Sociodemographic data, Prevalence of co-morbid conditions and Usage pattern for co-prescribed drugs - Switching pattern to Escitalopram & Clonazepam FDCTimepoint: Baseline;- Adverse events reported at the end of the study - Clinical Global Impression for Efficacy Index (CGI-EI) at 12th weekTimepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactYakshdeep Dave
Torrent Pharmaceuticals Ltd.
Outcome results
None listed